OncoSec Medical Inc (ONCSQ)

[hschlauch]

I would think first line therapy is very much in the cards for stage III/IV melanoma. It would be most prudent for them to identity an optimal biomarker threshold in the first-line setting as you're alluding to, so that patients who might respond with anti-PD-1 monotherapy don't receive more treatment regimens than they need.

I certainly think EP pIL-12 with pembro would work in other solid cancers, but they would have to use the new GENESIS EP device if they're directly treating subcutaneous and visceral lesions. The first new PIIM construct is very likely going to be much better than Immunopulse IL-12 due to the fact that the genes are p2a linked and the PIIM includes encoded genes that will vastly improve antigen presentation and T cell activation while mitigating Treg effects intratumorally.

I will read up on HALO at some point and provide some feedback.